Skip to content

ARA 290 Intravenous-Subcutaneous crossover study in normal human volunteers - PKARA Study

ARA 290 Intravenous-Subcutaneous crossover study in normal human volunteers - PKARA Study - PKARA study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON37923
Enrollment
6
Registered
2012-02-10
Start date
2012-03-29
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuropathic pain pain

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers in the age range of 18-65 years

Exclusion criteria

Exclusion criteria: 1. Clinically relevant abnormal history of physical and mental health, as determined by medical history taking and physical examinations obtained during the screening visit and/or prior to the administration of the initial dose of the study drug (as judged by the investigator); 2. A semi recumbent systolic blood pressure of >150 mmHg and/or diastolic blood pressure of > 90 mmHg at screening; 3. History of alcoholism or substance abuse within three years prior to screening; 4. Negative pregnancy test 5. Male subjects habitually using more than 21 units of alcohol per week and female subjects using more than 14 units of alcohol per week; 6. Subject was a smoker or has used nicotine/nicotine-containing products within 3 months prior to screening; 7. Use of medication during the study period; 8. Subject is unable to refrain from food and drinks containing a xanthine (e.g. chocolate, cola, coffee or tea) during the study days 9. Male subject is unable/unwilling to use a medically acceptable method of contraception throughout the entire study period. Female subject is not using oral contraceptives, or is not post-menopausal (last menstrual period > 2 years ago and FSH > 25 IU/L), or surgically sterilized; 10. Subject has a history of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food; 11. Subject has a history of syncopal episodes; 12. Subjects that received a vaccination or immunization within the last month; 13. Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times per year; 14. Subject has undergone major surgery within three months prior to screening; 15. Donation or loss of blood (> 500 mL) within 3 months prior to screening; 16. Inadequate venous accessibility as judged by clinicians (physician or nurse); 17. Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well being of the subject

Design outcomes

Primary

MeasureTime frame
Plasma concentration of ARA290

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)